JP2023505176A - エクソソーム単離法 - Google Patents
エクソソーム単離法 Download PDFInfo
- Publication number
- JP2023505176A JP2023505176A JP2022533314A JP2022533314A JP2023505176A JP 2023505176 A JP2023505176 A JP 2023505176A JP 2022533314 A JP2022533314 A JP 2022533314A JP 2022533314 A JP2022533314 A JP 2022533314A JP 2023505176 A JP2023505176 A JP 2023505176A
- Authority
- JP
- Japan
- Prior art keywords
- exosomes
- sample
- tissue
- cell surface
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001808 exosome Anatomy 0.000 title claims abstract description 85
- 238000002955 isolation Methods 0.000 title description 10
- 210000004027 cell Anatomy 0.000 claims abstract description 44
- 229920001184 polypeptide Polymers 0.000 claims abstract description 34
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 34
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 34
- 238000000034 method Methods 0.000 claims abstract description 21
- 239000011324 bead Substances 0.000 claims description 35
- 210000001519 tissue Anatomy 0.000 claims description 33
- 210000003205 muscle Anatomy 0.000 claims description 31
- 210000002966 serum Anatomy 0.000 claims description 25
- 239000007787 solid Substances 0.000 claims description 13
- 102100025682 Dystroglycan 1 Human genes 0.000 claims description 10
- 108010071885 Dystroglycans Proteins 0.000 claims description 10
- 230000005291 magnetic effect Effects 0.000 claims description 9
- 210000003716 mesoderm Anatomy 0.000 claims description 7
- 210000000663 muscle cell Anatomy 0.000 claims description 7
- 239000013060 biological fluid Substances 0.000 claims description 6
- 230000000747 cardiac effect Effects 0.000 claims description 5
- 210000003981 ectoderm Anatomy 0.000 claims description 4
- 210000001900 endoderm Anatomy 0.000 claims description 4
- 239000000090 biomarker Substances 0.000 abstract description 3
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 230000008827 biological function Effects 0.000 abstract description 2
- 239000003814 drug Substances 0.000 abstract description 2
- 229940124597 therapeutic agent Drugs 0.000 abstract description 2
- 239000000523 sample Substances 0.000 description 43
- 101000855983 Homo sapiens Dystroglycan 1 Proteins 0.000 description 12
- 238000001262 western blot Methods 0.000 description 10
- 102000007623 Dystroglycans Human genes 0.000 description 8
- 210000003098 myoblast Anatomy 0.000 description 8
- 102100025222 CD63 antigen Human genes 0.000 description 7
- 101000934368 Homo sapiens CD63 antigen Proteins 0.000 description 7
- 239000000872 buffer Substances 0.000 description 7
- 239000006143 cell culture medium Substances 0.000 description 7
- 102100027221 CD81 antigen Human genes 0.000 description 6
- 101000914479 Homo sapiens CD81 antigen Proteins 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000012149 elution buffer Substances 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000000749 co-immunoprecipitation Methods 0.000 description 4
- 210000003722 extracellular fluid Anatomy 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 239000004593 Epoxy Substances 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 102000046916 human DAG1 Human genes 0.000 description 3
- 238000003312 immunocapture Methods 0.000 description 3
- 238000001114 immunoprecipitation Methods 0.000 description 3
- 238000001964 muscle biopsy Methods 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 206010003445 Ascites Diseases 0.000 description 2
- 108010052285 Membrane Proteins Proteins 0.000 description 2
- 108700011259 MicroRNAs Proteins 0.000 description 2
- 208000018737 Parkinson disease Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 210000004381 amniotic fluid Anatomy 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000004408 hybridoma Anatomy 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 210000002977 intracellular fluid Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 210000004910 pleural fluid Anatomy 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000013049 sediment Substances 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 240000007241 Agrostis stolonifera Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 101150109411 DAG1 gene Proteins 0.000 description 1
- 102100036912 Desmin Human genes 0.000 description 1
- 108010044052 Desmin Proteins 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 239000011542 SDS running buffer Substances 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 229930185229 antidesmin Natural products 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 210000000852 deltoid muscle Anatomy 0.000 description 1
- 210000005045 desmin Anatomy 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000012645 endogenous antigen Substances 0.000 description 1
- 125000003700 epoxy group Chemical group 0.000 description 1
- 125000002573 ethenylidene group Chemical group [*]=C=C([H])[H] 0.000 description 1
- 102000013361 fetuin Human genes 0.000 description 1
- 108060002885 fetuin Proteins 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 239000012742 immunoprecipitation (IP) buffer Substances 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 230000035992 intercellular communication Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 210000001665 muscle stem cell Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000005298 paramagnetic effect Effects 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- ALZJERAWTOKHNO-UHFFFAOYSA-M sodium;dodecyl sulfate;3-morpholin-4-ylpropane-1-sulfonic acid Chemical compound [Na+].OS(=O)(=O)CCCN1CCOCC1.CCCCCCCCCCCCOS([O-])(=O)=O ALZJERAWTOKHNO-UHFFFAOYSA-M 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0658—Skeletal muscle cells, e.g. myocytes, myotubes, myoblasts
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5002—Partitioning blood components
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54313—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being characterised by its particulate form
- G01N33/54326—Magnetic particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/34—Muscles; Smooth muscle cells; Heart; Cardiac stem cells; Myoblasts; Myocytes; Cardiomyocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4707—Muscular dystrophy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
- G01N2400/02—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates involving antibodies to sugar part of glycoproteins
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
(a)エクソソームを含む試料を提供する工程;
(b)エクソソーム上の細胞表面ポリペプチドを同定する工程;
および
(c)エクソソーム上の前記細胞表面ポリペプチドを用いてエクソソームを単離する工程、
を含み、
ここで前記細胞表面ポリペプチドはジストログリカン(DAG)である。
(a)エクソソームを含む試料を提供する工程;
(b)エクソソーム上の細胞表面ポリペプチドを同定する工程;
(c)前記細胞表面ポリペプチドの結合パートナーを提供する工程;
(d)前記結合パートナーを前記試料に接触させる工程;
(e)前記結合パートナーを単離する工程、
および
(f)エクソソームを単離する工程、
を含み、
ここで前記細胞表面ポリペプチドはジストログリカン(DAG)である。
以下に添付図面を参照しながら本発明の実施態様を説明する。
参加者および倫理審査による承認
健常対象の三角筋生検は、欧州勧告およびフランス法にしたがうBTR(研究のための組織バンク(Bank of Tissues for Research)、EUネットワークEuroBioBankのパートナー)から取得した。
簡単に説明すると、既報(Bigotら、2015)のように、筋肉生検を機械的に分離して、プレート中の増殖培地(1容のM199、4容のダルベッコ変法イーグル培地(DMEM)、20%ウシ胎仔血清(v:v)、25μg/mlのフェチュイン、0.5ng/mlのbFGF、5ng/mlのEGF、5μg/mlのインスリン)に播種した。既報(Bigotら、2015)のように、CD56磁気ビーズを用いて筋原細胞集団を濃縮し、それらの筋原性に関しては抗デスミン抗体を用いて濃縮を行った。最少でも80%の細胞集団がデスミンに対して陽性であった。次いで、既報(Thorleyら、2016)にしたがい、筋芽細胞を不死化した。その後、不死化筋芽細胞を筋管に分化させて、それらをDMEMで3回すすいだ後、残存するFBS全てを除去してからDMEMで3日間培養した。
簡単に説明すると、赤色トップの採血用チューブを用いて、静脈穿刺により血液試料を採取し、室温で30分間凝固させた。4℃、4,000gで10分間遠心分離した後、血清をドライアイス上で瞬間凍結し、処理まで-80℃で保存した。
以下に、非限定的実施例を参照しながら本発明の実施態様について説明する。
筋肉エクソソームの単離
ポリペプチドジストログリカン(DAG)が、筋肉エクソソームの内部に存在するか、あるいは表面に存在するのか(膜に埋め込まれており、そのため抗体に接触可能)を判定するために、市販の抗DAG抗体(前記ポリペプチドの異なる形態を標的とする抗DAG抗体)が細胞培養培地から抽出した筋肉エクソソームに結合可能であるか否かを調べた。
(1)市販の抗DAG抗体でプルダウン(沈降)したエクソソームは、エクソソームマーカーに陽性であるか?;
および
(2)エクソソームマーカーでプルダウン(沈降)したエクソソームは、ポリペプチド・ジストログリカン(DAG)に陽性であるか?
このような方法で、市販の抗DAG抗体が標的とするポリペプチド・ジストログリカン(DAG)の形態がエクソソーム表面に存在するときのみ、これら両方の試験で陽性の結果が得られるはずである。αジストログリカン(DAG1遺伝子によってコードされる)が抗体に接触可能であって、そのため免疫親和性プルダウン(沈降)に適していることを、本発明者らが判定可能であることがこのアプローチを用いて示された(図1を参照のこと)。
血清中の細胞培養エクソソームの免疫捕捉
血清のような複合出発材料からの筋肉エクソソームの免疫捕捉が内因性血清IgGの競合により妨害されるか否かを試験するために、細胞培養培地の筋肉エクソソームを、パーキンソン病の患者および年齢と性別の一致した健常対象(上記のプロトコルNCT02305147)から取得したヒト血清試料に注入し、上記のように免疫共沈降(Co-IP)を行った。
循環筋肉エクソソームの抽出
抗DAG1免疫親和性アプローチを用いて、循環筋肉エクソソームを血清から単離可能か否かを調べるために、ヒト対象の血清を用いた。
健常対象の循環筋肉エクソソームの免疫捕捉
循環筋肉エクソソームを健常対照の血清から抗DAG1ビーズによって単離可能か否かを判定するために、試料容積を500μlに増やして上記のように免疫沈降を行った。捕捉エクソソームを抗DAG1単離ビーズから溶離させる溶離能についても、異なる溶出緩衝液を用いて試験した。
Claims (11)
- エクソソームを単離する方法であって、前記方法が:
(a)エクソソームを含む試料を提供する工程;
(b)エクソソーム上の細胞表面ポリペプチドを同定する工程;
(c)前記細胞表面ポリペプチドの結合パートナーを提供する工程;
(d)前記結合パートナーに前記試料を接触させる工程:
(e)前記結合パートナーを単離する工程、
および
(f)前記エクソソームを単離する工程、
を含み、
ここで前記細胞表面ポリペプチドはジストログリカン(DAG)である、方法。 - 請求項1の方法であって、ここで前記試料が生体液試料である、方法。
- 請求項1または2の方法であって、ここで前記試料が血清試料である、方法。
- 請求項1~3のいずれか1項に記載の方法であって、ここで前記試料が生体組織を含む、方法。
- 請求項1~4のいずれか1項に記載の方法であって、ここで前記試料が内胚葉組織、中胚葉組織、および外胚葉組織から選択される生体組織を含む、方法。
- 請求項5の方法であって、ここで前記中胚葉組織が筋肉組織である、方法。
- 請求項6の方法であって、ここで前記筋肉組織が骨格(横紋)筋細胞;平滑(非横紋)筋細胞;および心(半横紋)筋細胞から選択される細胞を含む、方法。
- 請求項1~7のいずれか1項に記載の方法であって、ここで前記細胞表面ポリペプチドがαジストログリカンである、方法。
- 請求項1~8のいずれか1項に記載の方法であって、ここで前記細胞表面ポリペプチドの前記結合パートナーが、前記細胞表面ポリペプチドに結合可能な抗体である、方法。
- 請求項1~9のいずれか1項に記載の方法であって、ここで前記細胞表面ポリペプチドの前記結合パートナーが、前記細胞表面ポリペプチドおよび固体支持体に結合可能な抗体を含む、方法。
- 請求項10の方法であって、ここで前記固体支持体が磁気ビーズである、方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB1917698.1 | 2019-12-04 | ||
GBGB1917698.1A GB201917698D0 (en) | 2019-12-04 | 2019-12-04 | A method of isolating exosomes |
PCT/EP2020/084640 WO2021110920A1 (en) | 2019-12-04 | 2020-12-04 | A method of isolating exosomes |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2023505176A true JP2023505176A (ja) | 2023-02-08 |
Family
ID=69147090
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022533314A Pending JP2023505176A (ja) | 2019-12-04 | 2020-12-04 | エクソソーム単離法 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230003726A1 (ja) |
EP (1) | EP4069825A1 (ja) |
JP (1) | JP2023505176A (ja) |
CN (1) | CN115279894A (ja) |
CA (1) | CA3160415A1 (ja) |
GB (1) | GB201917698D0 (ja) |
WO (1) | WO2021110920A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113671185A (zh) * | 2021-08-23 | 2021-11-19 | 安龄(上海)生物科技有限公司 | 一种外泌体识别装置及方法 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017054086A1 (en) * | 2015-10-01 | 2017-04-06 | Exerkine Corporation | Treatment of genetic myopathies using bioengineered exosomes |
WO2018081478A1 (en) * | 2016-10-26 | 2018-05-03 | The Broad Institute, Inc. | Exosomes and uses thereof |
CN106841613A (zh) * | 2017-01-18 | 2017-06-13 | 上海良润生物医药科技有限公司 | 一种检测外泌体的方法及体系 |
CN111133106A (zh) * | 2017-07-12 | 2020-05-08 | 外来体诊断公司 | 用于分离和富集生物流体来源的细胞外囊泡的方法及其使用方法 |
CN111212653A (zh) * | 2017-08-15 | 2020-05-29 | 儿童医学中心公司 | 经纯化间充质干细胞外排体及其用途 |
GB201717446D0 (en) * | 2017-10-24 | 2017-12-06 | Evox Therapeutics Ltd | Affinity purification of engineering extracellular vesicles |
GB201807178D0 (en) * | 2018-05-01 | 2018-06-13 | Univ Ulster | A method of diagnosing or prognosing a neurological disorder |
-
2019
- 2019-12-04 GB GBGB1917698.1A patent/GB201917698D0/en not_active Ceased
-
2020
- 2020-12-04 US US17/781,498 patent/US20230003726A1/en active Pending
- 2020-12-04 WO PCT/EP2020/084640 patent/WO2021110920A1/en unknown
- 2020-12-04 CN CN202080093602.XA patent/CN115279894A/zh active Pending
- 2020-12-04 EP EP20820835.5A patent/EP4069825A1/en active Pending
- 2020-12-04 JP JP2022533314A patent/JP2023505176A/ja active Pending
- 2020-12-04 CA CA3160415A patent/CA3160415A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
EP4069825A1 (en) | 2022-10-12 |
GB201917698D0 (en) | 2020-01-15 |
CA3160415A1 (en) | 2021-06-10 |
WO2021110920A1 (en) | 2021-06-10 |
US20230003726A1 (en) | 2023-01-05 |
CN115279894A (zh) | 2022-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Vaswani et al. | A method for the isolation and enrichment of purified bovine milk exosomes | |
CN105723221B (zh) | 分离方法、检测方法、信号测定方法、疾病的判定方法、疾病治疗药的药效评价方法、试剂盒以及液态组合物 | |
CN105934670B (zh) | 用于分离外泌体的方法 | |
US5891651A (en) | Methods of recovering colorectal epithelial cells or fragments thereof from stool | |
WO1994007138A1 (en) | Detection of specific target cells in specialized or mixed cell population and solutions containing mixed cell populations | |
WO2009140876A1 (zh) | 从生物体液样本中富集与检测稀有细胞的整合方法 | |
WO1997037226A9 (en) | Methods of recovering colorectal epithelial cells or fragments thereof from stool | |
JP2000508171A (ja) | 希少細胞の富化方法 | |
US20200132682A1 (en) | Methods and kits for exosome isolation and quantification | |
US20150132738A1 (en) | Method For Identification Of Non-Hematogeneous Karocytes Enriched From Body Fluid Of Humans Or Animals | |
WO2016186215A1 (ja) | 分離方法、検出方法、シグナル測定方法、疾患の判定方法、薬効評価方法、キット、液状組成物及び検体希釈液 | |
JP2023505176A (ja) | エクソソーム単離法 | |
US9213029B2 (en) | Method for diagnosing breast cancer by detection of polymeric immunoglobulin receptor in vesicles isolated from patients | |
Svobodová et al. | Dot-ELISA affinity test: an easy, low-cost method to estimate binding activity of monoclonal antibodies | |
WO2016121821A1 (ja) | 分離方法、検出方法、シグナル測定方法、疾患の判定方法、薬効評価方法、キット、液状組成物及び検体希釈液 | |
Wu et al. | Positively charged magnetic nanoparticles for capture of circulating tumor cells from clinical blood samples | |
WO2022001826A1 (zh) | 一种检测胰腺癌患者外周血循环肿瘤细胞E-Cadherin表达的免疫荧光试剂盒 | |
US20100221742A1 (en) | Novel cancer associated antibodies and their use in cancer diagnosis | |
WO2021193802A1 (ja) | 肺がん患者に対する免疫チェックポイント阻害剤による治療の有効性を予測するための方法 | |
KR20230114327A (ko) | 태아 세포의 단리, 검출 및 분석을 위한 조성물 및방법 | |
TW202120696A (zh) | 胞外體的分離與檢測方法、以及分離與檢測套組 | |
KR20150114558A (ko) | 인독실 황산의 측정 방법 | |
RU2800988C1 (ru) | Способ иммунофенотипирования лейкоцитов в тканях органов свиней и на мазках крови с использованием непрямой иммуногистохимической реакции на основании моноклональных антител | |
LU500787B1 (en) | Isolation and detection of cdcp1 positive circulating tumor cells | |
CN115819548B (zh) | 一种检测炎症相关疾病的标志物和方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20231127 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20240522 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20240523 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20240830 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240910 |